On Thursday, Sanofi SA (NASDAQ:SNY) reported new results from the GMMG-HD7 phase 3 study of Sarclisa in combination with lenalidomide, bortezomib, and dexamethasone (RVd) versus RVd induction followed by post-transplant re-randomization to Sarclisa plus lenalidomide versus lenalidomide maintenance in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients. The data show that Sarclisa, combined with RVd during induction therapy, significantly prolonged progression-free survival (PFS), resulting in a statistically significant and clinically meaningful reduction in disease progression or death compared to RVd induction regardless of the maintenance regimen. In December 2021, Sanofi and GMMG shared the results from part one, which met ...